Seeking Alpha

Seeking Alpha Portfolio App for iPad

764 people get DRRX articles and Market Currents by email alert.

Get email alerts on DRRX »

DRRX

Durect Corporation

6/19/2013, 7:43 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 12:52 PM Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%. Comment! [On the Move]
Friday, May 10, 8:29 AM The sell-off in shares of Durect (DRRX) has accelerated meaningfully as the stock is now down 37% premarket after Pfizer's Remoxy comments. Reminder: DRRX is entitled to royalties of between 6% and 11.5% of potential Remoxy net sales which some analysts have said could ultimately hit $1B if the drug reaches market. The impact for DRRX, which only had $53.1M in total revenue in 2012, really cannot be overstated. See SA contributor PropThink's recent analysis for more. (Also: PTIE crashes on PFE comments) 1 Comment [Healthcare, On the Move]
Friday, May 10, 7:46 AM Pfizer (PFE) updates Durect (DRRX) on Remoxy, saying that it's "considering its options", and that if it elects to continue development of Remoxy, "we would not expect to submit a response to the "complete response" letter before mid-2015." (PR) This is less positive than expected by SA author Jason Napodano; shares are -12.6% premarket. 1 Comment [Healthcare, On the Move, Breaking News]
Friday, May 3, 6:49 AM Durect (DRRX): Q1 EPS of -$0.05 beats by $0.02. Revenue of $4.2M beats by $0.33M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 30, 12:46 PM Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move]
Tuesday, April 30, 11:41 AM Pain Therapeutics (PTIE +19%) and Durect (DRRX +25.5%) both soar on the back of positive comments out of Pfizer's (PFE) conference call about Remoxy, an oxycodone capsule the pair have been developing. PTIE sub-licensed Remoxy's commercialization rights to King Pharmaceuticals, which is a subsidiary of PFE, and the pharma-giant noted in its call that it's had a productive meeting with the FDA last month regarding the drug. (PFE Conference Call Webcast) 1 Comment [Healthcare, On the Move]
Tuesday, April 16, 7:51 AM Durect (DRRX) submits NDA for POSIDUR, a non-opioid, long-acting local anesthetic for the treatment of post-surgical pain. The company, which is also developing an abuse-resistant form of oxycodone, notes that non-opioid options for the management of pain post-surgery can hasten recovery and shorten hospital stays.
Comment! [Healthcare]
Monday, March 25, 9:20 AM Durect (DRRX) started at Buy at Stifel Nicolaus, price target $3. 1 Comment [Healthcare]
Thursday, February 28, 5:24 PM Durect (DRRX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $3.26M misses by $1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, January 3, 8:45 AM Zogenix (ZGNX) +5.8% after saying its Relday treatment for schizophrenia had a good safety and PK (pharmacokinetic - what the body does to the drug) profile in a Phase I study, which will now be extended for increased doses. Durect (DRRX) is also on watch, as Zogenix has licensed Durect's technology for use in Relday. (PR) Comment! [Healthcare, On the Move]
Thursday, November 1, 2012, 12:45 PM Midday top 10 gainers: HGSH +78%. WMCO +41%. KSWS +35%. CHC +32%. REDF +26%. GTIV +23%. WNC +22%. IMH +20%. JDAS +17%. NEWP +16%. Midday top 10 Losers: CMVT -48%. DRRX -39%. PTIE -30%. ABMD -30%. FARO -18%. AAWW -17%. FBN -16%. GBX -14%. ZUMZ -14%. EONC -14%. Comment!
Monday, August 6, 2012, 4:26 PM Durect (DRRX): Q2 EPS of $0.05 in-line. Revenue of $4.8M misses by $1M. Shares +1.6% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Thursday, January 5, 2012, 5:58 PM Durect (DRRX) drops 46.6% AH after stating Phase III trial results for its Posidur post-operative pain-relief drug "did not reach statistical significance." The company says it will now "hold a pre-NDA meeting with the FDA" to discuss the results. (previously) Comment! [Healthcare, On the Move]
Monday, June 27, 2011, 3:54 PM Pain Therapeutics (PTIE -24.7%) is Nasdaq's leading loser for the second straight session, adding to Friday's 40%-plus drop after the FDA rejected a new drug application for Remoxy, its extended release capsules of oxycodone developed with Pfizer (PFE +0.4%). Durect (DRRX -8.5%), whose technology was used to develop the drug, also adds to losses. Comment! [Healthcare, On the Move]
Monday, June 27, 2011, 9:10 AM Premarket gainers: CNU +32%. LDK +6%. ACUR +6%. ZLCS +5%. SGMO +4%. ALU +3%. SINA +3%. ERIC +3%. ASML +3%.
Losers: PTIE -29%. DRRX -16%. XCO -4%. CTIC -3%. RDN -3%. Comment! [On the Move]
Friday, June 24, 2011, 11:11 AM Durect (DRRX -28%) is another casualty of the FDA's rejection of Remoxy. Its technology - designed to discourage common methods of tampering - was used to develop the drug. PTIE -37%, PFE -1.5%. Comment! [Healthcare, On the Move]